Nasdaq

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...
Seeking Alpha

GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access ...
Nasdaq

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication

GeneDx Recognizes Cerebral Palsy Awareness Month with Commitment to Improve Access to Testing GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes ...
Seeking Alpha

Reviewing GeneDx Holdings: Exome Testing And EPIC Aura Integration Make It A GARP 'Buy'

GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and ...
Business Wire

GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing

Designation highlights GeneDx innovation in clinical whole genome and whole exome testing and accelerates the pathway for FDA authorization of these novel diagnostic tests GAITHERSBURG, Md.--(BUSINESS ...

GeneDx falls after reporting Q4 and FY25 revenue

GeneDx reported full-year 2025 revenue of approximately $427M, inline with consensus of $427M, representing a 41% ...
The New England Journal of Medicine

High-Resolution and Noninvasive Fetal Exome Screening

We evaluated the feasibility of high-resolution noninvasive prenatal screening in 51 pregnancies that were representative of the pregnant population receiving care at the recruitment hospital (Tables ...